Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

Jennifer R. King, Edward P. Acosta, Ram Yogev, Andrew Wiznia, Joyce Kraimer, Bobbie Graham, Vincent Carey, Paula Britto, Patrick Jean-Philippe, John Moye, Douglas Watson

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.

Original languageEnglish (US)
Pages (from-to)159-161
Number of pages3
JournalPediatric Infectious Disease Journal
Volume28
Issue number2
DOIs
StatePublished - Feb 2009

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients'. Together they form a unique fingerprint.

Cite this